Suppr超能文献

CIBMTR 一年生存结果计算器的应用作为回顾性分析的工具。

Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis.

机构信息

Department of Medicine, Stem Cell Transplantation and Cellular Therapy Service, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.

Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Bone Marrow Transplant. 2023 Oct;58(10):1089-1095. doi: 10.1038/s41409-023-02031-2. Epub 2023 Jul 8.

Abstract

The Web-based One Year Survival Outcomes Calculator developed by the Center for International Blood and Marrow Transplant Research (CIBMTR) applies large-scale registry data to generate individualized estimates of overall survival (OS) probability 1 year after first allogeneic hematopoietic cell transplant (HCT) and can therefore provide a data-driven foundation for personalized patient counseling. We assessed the calibration of the CIBMTR One Year Survival Outcomes Calculator when applied to retrospective data among adult recipients of first allogeneic HCT for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS) with peripheral blood stem cell transplant (PBSCT) from a 7/8- or 8/8-matched donor from 2000 through 2015 at a single center. Predicted 1 year OS was estimated for each patient using the CIBMTR Calculator. Corresponding observed 1 year OS was estimated for each group by the Kaplan-Meier method. A weighted Kaplan-Meier estimator was used to visually display the average of observed 1 year survival estimates over the continuous range of predicted OS. In the first analysis of its kind, we demonstrated that the CIBMTR One Year Survival Outcomes Calculator could be applied to larger patient cohorts and predicted 1 year prognosis with general agreement between predicted and observed survival.

摘要

由国际血液和骨髓移植研究中心(CIBMTR)开发的基于网络的一年生存结果计算器应用大规模注册数据生成首次异基因造血细胞移植(HCT)后 1 年总体生存(OS)概率的个体估计值,因此可以为个性化患者咨询提供数据驱动的基础。我们评估了 CIBMTR 一年生存结果计算器在应用于单中心 2000 年至 2015 年间接受 7/8 或 8/8 匹配供体外周血干细胞移植(PBSCT)的成人急性髓系白血病(AML)、急性淋巴细胞白血病(ALL)或骨髓增生异常综合征(MDS)首次异基因 HCT 患者的回顾性数据时的校准情况。使用 CIBMTR 计算器为每位患者估计 1 年 OS。通过 Kaplan-Meier 方法为每个组估计相应的观察 1 年 OS。加权 Kaplan-Meier 估计器用于直观显示观察到的 1 年生存估计值在预测 OS 连续范围内的平均值。在这种分析的首次应用中,我们证明了 CIBMTR 一年生存结果计算器可以应用于更大的患者队列,并预测 1 年预后,预测和观察到的生存之间存在普遍一致性。

相似文献

1
Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis.
Bone Marrow Transplant. 2023 Oct;58(10):1089-1095. doi: 10.1038/s41409-023-02031-2. Epub 2023 Jul 8.
6
Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.
Blood. 2014 Oct 16;124(16):2596-606. doi: 10.1182/blood-2014-05-576041. Epub 2014 Aug 26.
7
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2019 Mar;25(3):606-612. doi: 10.1016/j.bbmt.2018.09.012. Epub 2018 Sep 19.
9
Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.
Ann Hematol. 2018 Dec;97(12):2491-2500. doi: 10.1007/s00277-018-3454-y. Epub 2018 Jul 31.

本文引用的文献

1
The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT.
Blood Adv. 2022 Mar 8;6(5):1525-1535. doi: 10.1182/bloodadvances.2021004319.
4
Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation.
Biol Blood Marrow Transplant. 2019 Sep;25(9):1884-1889. doi: 10.1016/j.bbmt.2019.05.015. Epub 2019 May 22.
5
Precision oncology for acute myeloid leukemia using a knowledge bank approach.
Nat Genet. 2017 Mar;49(3):332-340. doi: 10.1038/ng.3756. Epub 2017 Jan 16.
7
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.
Blood. 2014 Jun 5;123(23):3664-71. doi: 10.1182/blood-2014-01-552984. Epub 2014 Apr 17.
10
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
Blood. 2005 Oct 15;106(8):2912-9. doi: 10.1182/blood-2005-05-2004. Epub 2005 Jun 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验